Key facts
- It has raised $3.2M across 3 recorded rounds; the latest was Seed Round ($600K) in Jun 2023.
- ImmunoProfile has filed 7 Form Ds with the SEC since 2020, most recently Nov 2024 ($150K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for ImmunoProfile
Funding rounds
3 roundsAbout ImmunoProfile
Developer of an at-home diagnostic test system designed to determine vulnerability to infectious disease. The company's system offers individuals a convenient way to test their immunity levels and make informed decisions about their health, enabling people to take control of their vaccine protection status.
- Sector
- Healthcare
- HQ
- Naples, FL, United States
- Founded
- 2013
- Website
- immunoprofile.com/
- Ownership
- Privately Held (backing)
ImmunoProfile doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ImmunoProfile shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ImmunoProfile in its N-PORT filings yet. We sweep new filings monthly.